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Abstract
The treatment of headache disorders is adapted to their severity. It is the aim of this study to evaluate the probability of treatment
decisions being taken and to identify underlying principles influencing them. The study was internet-based and cross-sectional;
participants completed the EUROLIGHT questionnaire anonymously. Inclusion criterion was the consent to participate.
Participants were excluded if diagnostic questions had not been completed. We estimated probabilities based on relative fre-
quencies and built binary logistic regression models to identify factors influencing decision-making. The survey was completed
by 976 individuals; 636 completed the diagnostic questions. The probability of a patient to consult a GP or a neurologist was 0.26
and 0.20, respectively. Patients decided by a probability of 0.93 to take acute treatment. These treatment decisions, which were
taken by patients alone increased in probability with increasing ictal burden (P < 0.001,P < 0.001 and P < 0.001). The probability
of treating migraine with triptans was 0.74; the probability to take a prophylactic treatment was 0.43. Neurologists were more
likely than GPs to prescribe these medications (P = 0.006 and P < 0.001, respectively). We identified several principles under-
lying treatment decisions. Most patients decide to take acute treatment for headache attacks; they are less likely to treat their
headache disorder interictally. Treatment decisions are less likely to be taken if more than one decision-maker is involved; if
physicians are involved, severity of the headache disorder does not affect the probability of a treatment decision being taken.
Overall, the more severely affected a headache patient, the less likely an adequate treatment.
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Headache disorders affect patients’ lives to varying extent.
While some suffer only occasional attacks hardly affecting
their everyday lives, others find their well-being curtailed
[20]. Guidelines consequently advise tailoring treatment regi-
mens to individual needs [3, 5, 16, 17].
Finding an adequate therapy is not straightforward. Of sev-
eral available remedies, patients and physicians choose by trial
and error. When headache attacks increase in frequency, tak-
ing a prophylactic treatment may prove beneficial [17]. Non-
pharmacological treatment approaches help many [1], but are
more difficult to apply and time-consuming than simply tak-
ing a pill. Referral to a headache expert may be necessary
when the ictal burden rises [18].
However, the effort of treating a headache disorder in-
creases with its severity, as treatment needs to be escalated.
Furthermore, treatment will only be administered if patients
(and—in the case of prescription drugs—their doctors) decide
to do so. Severely affected headache patients need to work
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their way up to an adequate treatment regimen, and some
might never reach an adequate level [10, 26]. Little is known
about the number of patients who give up (or are given up)
despite remaining treatment options.
It is the aim of this study to estimate in a real-life sample the
probabilities of decisions about headache treatment being tak-
en and to identify underlying principles.
Methods
Study Design, Inclusion and Exclusion Criteria
We conducted an internet-based study and invited potential
participants through posters, journal articles and web pages to
complete the EUROLIGHT questionnaire [2]; data were col-
lected anonymously. Inclusion criterion was the consent to
participate. We excluded participants who had not answered
all diagnostic questions. Headache phenotypes were assessed
as published [19].
Recruitment/enrolment was initiated in March 2019 and
halted in March 2020. As data were collected anonymously,
no formal ethical approval was necessary according to Swiss
legislation.
Outcome Measures
In this study, we aim to estimate the probability of a treatment
decision A being taken, provided that the premises B are met,
i.e. P(A| B). The probabilities P(A), P(B) as well as P(A∩ B)
are estimated based on the collected data (empirical probabil-
ity); P(A| B) will be calculated according to Eq. 1. The deci-
sions (A) to be analysed as well as their premises (B) are listed
in Table 1.




Next, we built binary logistic regression models (BLR) for
decisions 1 to 4.1 and 5.1 (Table 3) to identify covariates that
influence the probability of decision A being taken, premises
B being met. Sex, occupation (working and studying vs. un-
employment, retirement and homemaker) and headache phe-
notype (migraine vs. TTH), as well as age, the number of
headache days during the last 30 days, the number of days
on which the participants were unable to work during the last
30 days because of headaches and the scores of the depression
and anxiety subscales of the Hospital Anxiety and Depression
Scale [27], were included as covariates. In addition, for deci-
sions 4.1 and 5.1, we included the speciality of the treating
physician (neurology vs. general medicine) into the model.
Covariates in the final model were chosen using a stepwise
backward selection method; a variable was removed if the
probability of its score statistic was above 0.05.
Statistical Analysis
Statistical analyses were performed with IBM SPSS statistics,
version 25. We estimated probabilities based on relative fre-
quencies (empirical probabilities); probabilities are reported as
ranging from 0 to 1, and proportions as percentages. Average
values are presented with their standard deviation and are
compared with other average values through analyses of var-
iance. Correlations are assessed with Pearson’s correlation
coefficient. We refer to missing values as “not reported”
(n.r.). Significance level was set at 0.05.
Results
The survey was completed by 976 individuals; 636 partici-
pants (54.7%) had responded to all diagnostic questions of
the EUROLIGHT questionnaire. Migraine was diagnosed in
376 (59.1%), probable migraine in 98 (15.4%), tension-type
headache (TTH) in 143 (22.5%) and probable TTH in 19
(3.0%). At least one headache attack during the last 30 days
had occurred in 616 of 634 participants (2 n.r.).
Only datasets of participants with identifiable headache
phenotypes were taken for further analysis. In the following,
the phenotypes migraine and probable migraine as well as the
phenotypes TTH and probable TTH are aggregated. The de-
mographic profile is detailed in Table 2.
Seeking Medical Advice
More than half of the participants had not consulted any doc-
tor for their headache disorder during the last 12 months (384/
608, 63.1%, 28 n.r.). Of those who had, 102 (45.5%) had been
treated by a GP alone, 66 by a neurologist (29.5%) and 56 by
both (25.0%).
The estimated probability of a person with headaches to
consult a GP was 0.26 (Table 1). The number of monthly
headache days (P < 0.001) and headache phenotype (P =
0.001) significantly influenced this probability according to
BLR (Table 3). A higher ictal burden was associated with an
increased probability; participants with migraine were more
likely to contact a GP (OR = 2.850, 95%-CI 1.509–5.384)
than patients with migraine were.
The estimated probability of a person to consult a neurolo-
gist for their headache was 0.20 (Table 1). BLR revealed that
the monthly number of headache days and the headache phe-
notype significantly influenced this decision (P < 0.001, P =
0.010, respectively). Migraine was associated with a higher
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likelihood of consulting a neurologist (OR = 2.586, 95%-CI
1.251–5.343, Table 3).
On average, participants who had not been treated by a doc-
tor had 6 ± 5 headache days per month, those treated by a GP
had 11 ± 8 days and participants treated by a neurologist (or
both a neurologist and a GP) had 13 ± 9 headache days (2
n.r.). The difference in headache days between patients treated
by no physician and any physician was significant (P < 0.001).
Those who consulted a GP had significantly less headache days
than those who consulted a neurologist (P = 0.048).
Table 1 Decision A and premise
B; probabilities P(A∩ B) and
P(B) were estimated based on
relative frequencies; P(A| B) was
calculated; the number of patients
eligible for decision A is listed in
the enumerator of the fractions in
the P(B) column
№ Decision A and premise B n.r. P(A∩ B) P(B) P(A| B)
1 BPatient has had at least one headache attack in life 28 158/608 608/608 0.26
APatient consults a GP for the headache
2 BPatient has had at least one headache attack in life 28 122/608 608/608 0.20
APatient consults a neurologist for the headache
3 BPatient has had at least one headache attack during the last
30 days
59 522/577 560/577 0.93
APatient uses NSAIDs to treat headache attacks
4.1 BPatient suffers from migraine, has had at least one attack
during the last 30 days, a pain intensity of moderate to
severe, and has sought a physician’s advice for his headache
attacks
149 122/487 164/487 0.74
APatient uses triptans to treat headache attacks
4.2 BPatient suffers from migraine, has had at least one attack
during the last 30 days, a pain intensity of moderate to
severe, and has sought a GP’s advice for his or her headache
attacks (and not a neurologist’s advice)
149 43/487 72/487 0.60
APatient uses triptans to treat headache attacks
4.3 BPatient suffers from migraine, has had at least one attack
during the last 30 days, a pain intensity of moderate to
severe, and has sought a neurologist’s advice for his or her
headache attacks
149 79/487 92/487 0.86
APatient uses triptans to treat headache attacks
5.1 BPatient suffers from 6 or more headache days per month and
has been treated for his headaches by a general practitioner
or a neurologist
30 73/606 168/606 0.43
APatient takes a prophylactic treatment
5.2 BPatient suffers from 6 or more headache days per month and
has been treated for his headaches by a general practitioner
(and not by a neurologist)
30 18/606 72/606 0.25
APatient takes a prophylactic treatment
5.3 BPatient suffers from 6 or more headache days per month and
has been treated for his headaches by a neurologist
30 55/606 96/606 0.57
APatient takes a prophylactic treatment
Table 2 Demographic profile of
the participants according to the
reported phenotype of their
headaches. TTH tension-type
headache, n.r. not reported
Migraine (N = 474) TTH (N = 162)
Age in years 40 ± 13 39 ± 12
0 n.r. 0 n.r.
Females (%) 392 (83.1%) 115 (59.6%)
2 n.r. 2 n.r.
Married or living with a partner (%) 306 (64.7%) 115 (71.9%)
1 n.r. 2 n.r.
Working or studying (%) 426 (90.1%) 155 (95.7%)
1 n.r. 0 n.r.
Headache days in the last month 9 ± 7 7 ± 7
1 n.r. 1 n.r.
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Treatment Decisions
Most participants took OTC medication (NSAIDs or paracet-
amol) to treat their headaches (532/578, 58 n.r.); the estimated
probability to take one of these drugs was 0.93 (Table 1). BLR
identified three factors that significantly influenced this
probability.
Migraine patients took NSAIDs or paracetamol more fre-
quently (OR= 3.256, 95%-CI 1.684–6.295, P < 0.001) than pa-
tients with TTH did. In addition, with increasing number of
headache days (P < 0.001), the number of dayswhen participants
had been unable to work (P < 0.001) increased, and the proba-
bility of taking OTC medication increased likewise (Table 3).
In Switzerland, triptans are available on prescription only.
Treatment with these medications was less common than a
treatment with OTC medication; 40.6% of all participants re-
ported taking triptans (200/493, 143 n.r.).
Migraineurs with a moderate or high pain intensity during
their attacks who had been treated by a GP or a neurologist
during the last 12 months had an estimated probability of 0.74
of taking—and thus having received a prescription for—
triptans (149 n.r.). The only factor significantly influencing
whether a patient took triptans was the speciality of her/his
physician (Table 3); patients being treated by a neurologist
were more likely to have received a prescription (OR =
2.655, 95%-CI 1.317–5.351, P = 0.006).
The Swiss Headache Association generally recommends
prescribing a prophylactic treatment to patients with migraine
suffering six or more headache days per month; no precise
cut-off value for a prophylactic treatment of TTH is provided
[3]. Half of all participants (50.8%, 322/634, 2 n.r.) had at least
six headache days per month. Of these, about one third had
consulted a doctor during the last 12months (27.7%, 168/606,
30 n.r.).
The probability of taking a prophylactic treatment was 0.43
in patients suffering from 6 or more headache days per month
and treated by a GP or a neurologist (Table 1).
The only covariate significantly influencing whether a pa-
tient was treated prophylactically was the specialty of the
treating physician (Table 3). Patients treated by a neurologist
were significantly more likely to take a prophylactic treatment
(OR = 4.415, 95%-CI 1.954–9.976, P < 0.001).
Table 3 Results of the binary logistic regression models; covariates in the final model were chosen using a stepwise backward selection method;
covariates with P < 0.05 were retained in the model. HADS-D Depression subscale of the Hospital Anxiety Depression Scale
№ Decision Number of
datasets
Covariate B P value Odds
Ratio
95%-CI
1 Patient has had at least one headache attack in
his/her life and decides to consult a GP for the
headache
447 Monthly headache days 0.90 P < 0.001 1.094 1.062–1.128
Headache phenotype* 1.047 P = 0.001 2.850 1.509–5.384
Constant − 2.721 P < 0.001 0.066
Chi square: 50.552, P < 0.001, Nagelkerke R2: 0.158, Classification accuracy 75.4%, Number of steps: 7
2 Patient has had at least one headache attack in
his/her life and decides to consult a neurologist
for the headache
447 Monthly headache days 0.115 P < 0.001 1.122 1.086–1.159
Headache phenotype* 0.950 P = 0.010 2.586 1.251–5.343
Constant − 3.304 P < 0.001 0.037
Chi square: 61.538, P < 0.001, Nagelkerke R2: 0.206, Classification accuracy 81.9%, Number of steps: 7
3 Patient has had at least one headache attack during
the last 30 days and decides to take NSAIDs or
paracetamol to treat attacks
423 Monthly headache days 0.208 P < 0.001 1.231 1.105–1.372
Headache phenotype* 1.180 P < 0.001 3.256 1.684–6.295
Number of days unable to
work
− 0.083 P < 0.001 0.921 0.883–0.960
Constant 0.384 P = 0.224 1.468
Chi square: 41.527, P < 0.001, Nagelkerke R2: 0.190, Classification accuracy 89.8%, Number of steps: 6
4.1 Patient suffers from migraine, has had at least one
attack during the last 30 days, has sought a
physician’s advice for his headache attacks, has a
pain intensity of moderate to severe and decides
to take triptans
144 Specialty of the treating
physician**
0.976 P = 0.006 2.655 1.317–5.351
HADS-D − 0.79 P = 0.030 0.924 0.860–0.993
Constant 0.536 P = 0.148 1.709
Chi square: 12.128, P = 0.002, Nagelkerke R2: 0.109, Classification accuracy 64.4%, Number of steps: 7
5.1 Patient suffers from ≥6 headache days per month,
has been treated for his headaches by a physician
and decides to take a prophylactic treatment
122 Specialty of the treating
physician**
1.485 P < 0.001 4.415 1.954–9.976
Constant − 1.340 P < 0.001 0.262
Chi square: 14.120, P < 0.001, Nagelkerke R2: 0.148, Classification accuracy 64.8%, Number of steps: 9
*An odds ratio above one implies that patients suffering from a migraine are more likely to take that medication than patients suffering from a TTH
**An odds ratio above 1 implies that patients treated exclusively by a GP are less likely to take that treatment than patients treated by neurologists or both
neurologists and GPs
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The probabilities of the assessed therapeutic decisions be-
ing taken (numbers 3, 4.1, 4.2, 4.3, 5.1, 5.2 and 5.3) correlated
highly (r = 0.57) with the number of eligible patients
(Table 1).
Discussion
We analysed the probabilities of decisions about headache
treatment being taken. The data suggest that whether a deci-
sion is probable or improbable depends mainly on several
principles underlying decision-making processes.
Decisions about headache treatment can be subdivided into
two subgroups depending on the number of decision-makers
involved. Patients choose by themselves to take OTC medi-
cation and to seek a physician’s advice. In decisions about
prescription drugs, a second decision-maker— the
prescriber—is involved.
Single decision-makers are likely to decide taking OTC
medication—almost everyone relied on a pharmacological
treatment (Table 1). BLR revealed that the most important
reasons were headache phenotype and ictal burden.
Consequently, to reduce impairment seems to be the most
important motivation to treat. This unsurprising finding sup-
ports the notion of pain conveying imperatives.
Imperativism is a philosophical theory suggesting that the
purpose of pain is to influence human behaviour (it “motivates
towards action”) [11]. In that aspect, pain resembles thirst and
hunger more closely than sensory input. Although migraine
attacks might be triggered by external factors [13, 14], remov-
ing these triggers is unlikely to interrupt the ongoing attack.
Consequently, taking acute treatment may be the only way
that quickly leads to pain freedom and thus responds to the
imperative.
The probability of a patient deciding to self-treat was
higher than the probability of a patient seeking a physician’s
advice. We suppose that the latter decision is taken interictally
in the absence of pain. This would suggest that consulting a
doctor is not a direct consequence of pain influencing human
behaviour through imperatives but the result of a cognitive
process to find a solution to repeated interruptions of well-
being.
The decision to consult a physician depends significantly
on the ictal burden (determined by pain phenotype and attack
frequency), suggesting that a reduction of impairment might
reduce the need for a physician. Although previous research
has pointed out that women are more likely to seek a physi-
cian’s advice for headache [7], our data do not corroborate that
finding. Also, anxiety and depression were not found to influ-
ence that decision.
Overall, the above-mentioned findings suggest that the
driving force behind decisions that patients take is the desire
to end pain and burden. Things change when a second
decision-maker comes into play.
Doctors offer additional means to reach patients’ therapeu-
t ic goals. Apart from providing information and
recommending non-pharmacological interventions, they may
prescribe triptans and prophylactic drugs.
Triptans are drugs that were developed to treat migraine.
While systematic reviews failed to find a general superiority
of triptans over NSAIDs [25], patients generally express great-
er satisfaction with the former [8]. It has been recommended
that migraine attacks be treated with triptans if pain intensity
can be expected to become moderate to severe [24]. Among
participants meeting these criteria, the empirical probability of
taking triptans was 0.74 (Table 1). This supports the conclu-
sion drawn in a previous study that too few migraine patients
receive triptans [10].
Furthermore, we estimated the probability of taking a pro-
phylactic drug among patients who had six or more headache
days per month. While some authors recommend taking pro-
phylactic drugs with different numbers of headache days [5,
16, 17], we felt that most headache experts would probably
agree that patients in this group might benefit from a prophy-
lactic treatment irrespective of their headache phenotype (mi-
graine and TTH).
As prophylactic drugs are taken daily, patients decide tak-
ing them in the absence of pain. Again, our data imply that
patients are less likely to decide taking a pill in the absence of
pain—the probability of taking triptans was 0.74, while that of
taking a prophylactic treatment was 0.43 (Table 1). This sec-
onds Katsavara et al. who found that too few patients receive
prophylactic drugs [10] but also suggests that patients prefer
treating pain when it is present—and not when it is not.
The probability of a patient receiving a prescription drug is
well below the probability of a patient taking OTCmedication
(Table 1). Other potential reasons left aside, this difference
may be due to the involvement of a second decision-maker.
Physicians decide with a certain probability to recommend
a treatment escalation and to prescribe a new medication; pa-
tients on the other side decide whether they are willing to take
it. As two positive assessments are necessary for the treatment
to be started, one might suspect that the probabilities of these
positive assessments are multiplied to calculate the probability
of a prescription being made. In this case, if the probabilities
were below 1, the product would be even smaller.
Our study design does not allow to measure the extent to
which patient and physician influence each other in decision-
making. However, if these decisions were taken completely
independently, it would be unlikely for of the patient to
consent—and perhaps irrational.
It is important to realize that while most patients have al-
ready used NSAIDs or paracetamol in the past, they are prob-
ably unfamiliar with triptans or prophylactic drugs. The prob-
ability of the state “treatment relieves pain” to occur is
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unknown to them (Table 4). If their physician did not give
some idea about what to expect, they would be taking a so-
called “decision under ignorance” [15].
Different ways have been proposed to take such a decision
[15]. For instance, pessimistic patients might try to prevent the
worst outcome (this strategy is called the “maximin princi-
ple”). In this case, they would probably refuse taking a new
medication as “equal amount of pain and side-effects” is the
least favourable outcome (Table 4). More optimistic patients
may choose the option with the best possible outcome.
However, whether the best option really is “less pain but
side-effects” depends on the amount of pain reduction and
the side-effects to be expected. If patients guessed that the
side-effects were horrible, it would be irrational to take the
pills. Consequently, they need advice and information.
We suspect that patients’ uncertainty is an important factor
that prevents treatment escalation. Therefore, it is mandatory
for doctors to give their patients an idea of what to expect. The
importance of the quality indicator “patients are given the
information they need to understand their headache and its
management,” which has been advanced by Steiner et al.
[21], cannot be overemphasized.
The regression models (Table 3) suggested that whether a
patient received a prescription drug mainly depended on the
specialty of the treating physician. In addition, patients with
more depressive symptoms were slightly less likely to receive
triptans. (Given that pessimistic attitudes may be part of a
depression [9], this finding suggests that these patients might
apply the “maximin principle”—see above—to take a
decision.)
Surprisingly, the ictal burden had no significant influence
on the likelihood of the prescription of a drug. (This finding
challenges the idea of patients and their physician sharing a
common therapeutic goal.) The reason for this is unknown but
we speculate that individual factors—notably on the doctor’s
side—are more relevant.
The importance of the physician’s specialty has been found
in a previous study [10] as well and is noteworthy.
Considering that neurologists escalate treatment more often,
the suggestion of referring severely affected patients from pri-
mary care to secondary or tertiary headache centres seems
reasonable [18]. However, this method also introduces obsta-
cles to treatment escalation because not everybody will be or
wants to be referred. If patients could contact healthcare pro-
viders on the required level themselves, they might obtain an
adequate treatment more easily or more quickly.
Furthermore, we found a high correlation between the
number of eligible patients and the probability of the decision
to treat being taken (Table 1). This suggests that decisions are
less likely to be taken the less frequently they arise. Given that
the number of eligible patients decreases with increasing dis-
ease severity (Table 1) and assuming that severely affected
patients should be treated with triptans and a prophylactic
treatment, these findings have an important implication: The
more severely affected a patient, the less likely is an adequate
treatment. This finding is supported by previous research [10,
26].
This conclusion is of even bigger concern as we analysed
only individual decisions and ignored that patients first need
to put themselves in a position where treatment decisions can
be taken. Before being able to decide taking an OTC drug,
patients must have gone to a pharmacy and bought a package.
Before deciding about taking a prescription drug, patients
must first find a doctor, make an appointment, wait for the
appointment, detail their symptoms and then—perhaps—re-
ceive information about further treatment options.
As we saw in the analysed decisions (Table 1), no decision
is taken with a probability of 1. Hence, some are going to “fall
by the wayside” at each step; the more steps required to obtain
a treatment, the smaller the proportion of patients receiving it.
Apart from allowing patients to contact headache specialists
directly if their ictal burden is sufficiently large, facilitating
access to advanced treatment approaches should be consid-
ered as well. For instance, following the example of some
countries [22, 23], triptans could be sold in pharmacies with-
out prescription.
A further issue contributing to the difficulty of receiving an
adequate treatment may be the diagnostic classification itself.
In the International Classification of Headache Disorders, sev-
eral migraine phenotypes are distinguished but only two de-
grees of ictal burden—episodic and chronic migraine—, the
latter being diagnosed too infrequently [4, 6]. Introducing into
the classification degrees of severity that are easy to discern
would offer the opportunity to guide treatment decisions.
We suggest distinguishing degrees of severity based on
ictal impairment, as these are the main reasons for patients
to seek a physician’s advice—see above. Subsequently,
guidelines might provide more binding recommendations for
each degree of severity. While patients and physicians may
decide to deviate from the recommendations, we believe that
this system would help making treatment escalations more
probable. This conclusion is supported by Lipton and co-
Table 4 Decisions to be made by
patients Treatment relieves pain Treatment does not relieve pain
Takes new medication Less pain but side-effects Equal amount of pain and side-effects
Does not take new medication Status quo Status quo
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workers. They found that adapting treatment to a patient’s
needs provided better clinical outcomes than escalating the
treatment if the results are unsatisfactory [12].
For instance, it could be suggested to treat a low-severity
migraine with NSAIDs, paracetamol or triptans. For medium
severity, a prophylactic agent may be added. For a high sever-
ity, an additional treatment such as onabotulinumtoxin A or
CGRP antagonists and inpatient care could be recommended.
Limitations
Some limitations need to be addressed. First, the sample is not
representative. Although many potential participants were in-
vited and many agreed to fill in the questionnaire, subgroups
of the target population might not have taken part. With the
study design not allowing assessment of the non-response
error, we focused on the relations between subgroups instead
of calculating prevalence rates.
Second, the probabilities listed in Table 1 are estimates
based on relative frequencies. In a larger sample, different
values might have been found. However, most conclusions
drawn in this article do not depend on precise values but on
relationships between values, which are more robust to
changes.
Third, although we aimed to analyse individual decisions,
most of them could be subdivided further into interim deci-
sions. More research is needed to investigate these as well as
the individual role of all participating decision-makers.
In addition, we only assessed the current headache frequen-
cy and did not ask for the headache frequency at the last
consultation. However, we assume that in patients who do
not receive a prophylactic treatment, the headache frequency
remains relatively stable.
The algorithm used to diagnose headache disorders distin-
guishes only between tension-type headache and migraine
[19]. Consequently, less common headache types like cluster
headache might have been missed and misclassified.
Finally, we did not correct for multiple testing. This deci-
sion was taken deliberately, as the purpose of this study was to
create new hypotheses rather than confirm pre-existing ones.
Conclusions
The data collected and analysed in this study suggest that deci-
sions about headache treatment are guided by several factors.
First, the probability of deciding to take an acute treatment
increases with the number of headache attacks; consequently,
the driving force behind the decision probably is the desire to
be pain-free. Second, patients are more willing to treat their
pain while in pain; the decision to treat and act prophylacti-
cally (while pain-free) is less probable.
Third, decisions about pharmacological treatments are less
likely to be taken if more than one decision-maker is involved.
Fourth, severity of the headache disorder does not influence
decisions about headache treatment if doctors are involved.
Fifth, if patients are not providedwith enough information about
side effects and the efficacy of a medication unknown to them,
they might act irrationally if they consented to the treatment.
Finally, the higher the number of steps necessary to obtain
a treatment, the smaller the probability of obtaining that treat-
ment. For patients with a higher ictal burden, more steps are
necessary to obtain advanced treatment approaches; hence,
the more severely affected a headache patient, the less likely
is an adequate treatment.
We propose different options to increase the probability of
adapting treatment to the degree of severity of the headache
disorder.
First, the number of decisions that can be taken by the
patient himself/herself could be increased. For instance,
triptans might be sold as OTC drugs. Second, the access to
specialized headache care could be eased. For instance, pa-
tients with a high ictal burden should be encouraged to contact
headache experts directly. In addition, the number of headache
experts may be increased. Third, doctors should make sure
that their patients have sufficient knowledge about efficacy
and side effects of a recommended treatment (e.g. with infor-
mation brochures [21]). Finally, more precise and binding
treatment recommendations with less room for interpretation
could be formulated. To facilitate that process, it may be help-
ful to include a higher number of degrees of severity that are
easy to diagnose into future versions of the headache
classification.
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